NICE invites Merck to submit CDF proposal for skin cancer drug

NICE invites Merck to submit CDF proposal for skin cancer drug PharmacoEconomics & Outcomes News 792, p33 - 2 Dec 2017 NICE invites Merck to submit CDF proposal for skin cancer drug NICE has asked Merck to submit a Cancer Drugs Fund (CDF) proposal for their immunotherapy drug, avelumab [Bavencio] – meaning patients with Merckel cell carcinoma will be able to access the drug while the company gathers more evidence for future resubmission to the NICE committee. NICE’s initial assessment showed that avelumab can extend patient survival compared with chemotherapy according to current clinical data; however, this evidence comes from one small trial and data is still being collected, so further evidence is needed to confirm these findings. Commenting on the announcement, Director of the Centre for Health Technology Evaluation at NICE, Professor Carole Longson, said "Merkel cell carcinoma is a rare and aggressive form of cancer. There are limited treatment options and the cancer can spread rapidly, which we know can be frightening for both patients and families . . . Avelumab is a promising treatment that has the potential to be cost effective. I hope Merck will work with us to submit a CDF proposal". NICE. Merck invited to submit a CDF proposal for Merkel cell cancer drug. Internet Document : 27 Nov 2017. Available from: URL: https://www.nice.org.uk/ news/article/merck-invited-to-submit-a-cdf-proposal-for-merkel-cell-cancer- drug 803286253 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png PharmacoEconomics & Outcomes News Springer Journals

NICE invites Merck to submit CDF proposal for skin cancer drug

Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/nice-invites-merck-to-submit-cdf-proposal-for-skin-cancer-drug-Iv06KeZ8H0
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
ISSN
1173-5503
eISSN
1179-2043
D.O.I.
10.1007/s40274-017-4556-9
Publisher site
See Article on Publisher Site

Abstract

PharmacoEconomics & Outcomes News 792, p33 - 2 Dec 2017 NICE invites Merck to submit CDF proposal for skin cancer drug NICE has asked Merck to submit a Cancer Drugs Fund (CDF) proposal for their immunotherapy drug, avelumab [Bavencio] – meaning patients with Merckel cell carcinoma will be able to access the drug while the company gathers more evidence for future resubmission to the NICE committee. NICE’s initial assessment showed that avelumab can extend patient survival compared with chemotherapy according to current clinical data; however, this evidence comes from one small trial and data is still being collected, so further evidence is needed to confirm these findings. Commenting on the announcement, Director of the Centre for Health Technology Evaluation at NICE, Professor Carole Longson, said "Merkel cell carcinoma is a rare and aggressive form of cancer. There are limited treatment options and the cancer can spread rapidly, which we know can be frightening for both patients and families . . . Avelumab is a promising treatment that has the potential to be cost effective. I hope Merck will work with us to submit a CDF proposal". NICE. Merck invited to submit a CDF proposal for Merkel cell cancer drug. Internet Document : 27 Nov 2017. Available from: URL: https://www.nice.org.uk/ news/article/merck-invited-to-submit-a-cdf-proposal-for-merkel-cell-cancer- drug 803286253 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792

Journal

PharmacoEconomics & Outcomes NewsSpringer Journals

Published: Dec 2, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve Freelancer

DeepDyve Pro

Price
FREE
$49/month

$360/year
Save searches from
Google Scholar,
PubMed
Create lists to
organize your research
Export lists, citations
Read DeepDyve articles
Abstract access only
Unlimited access to over
18 million full-text articles
Print
20 pages/month
PDF Discount
20% off